Safety of Human Papillomavirus Vaccines: An Updated Review (Q49564347)

21 February 2018

review article

1 reference

title

Safety of Human Papillomavirus Vaccines: An Updated Review (English)

1 reference

21 February 2018

1 reference

5

Kristine Macartney

1 reference

21 February 2018

author name string

Anastasia Phillips

1

1 reference

21 February 2018

Cyra Patel

2

1 reference

21 February 2018

Alexis Pillsbury

3

1 reference

21 February 2018

Julia Brotherton

4

1 reference

21 February 2018

publication date

26 December 2017

1 reference

21 February 2018

published in

Drug Safety

1 reference

21 February 2018

Epidemiology of Genital Human Papillomavirus Infection

cites work

1 reference

12 December 2020

Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study.

1 reference

12 December 2020

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

12 December 2020

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

1 reference

12 December 2020

Human papillomavirus and cervical cancer

1 reference

12 December 2020

Autoimmune diseases after adolescent or adult immunization: what should we expect?

1 reference

12 December 2020

What is "quality of evidence" and why is it important to clinicians?

1 reference

12 December 2020

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

1 reference

12 December 2020

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

12 December 2020

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

1 reference

12 December 2020

Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine

1 reference

12 December 2020

Beyond cervical cancer: burden of other HPV-related cancers among men and women

1 reference

12 December 2020

Guillain–Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006–2009

1 reference

12 December 2020

Comment on the contribution by Souayah et al., “Guillain–Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006–2009”

1 reference

12 December 2020

GRADE guidelines: 3. Rating the quality of evidence

1 reference

12 December 2020

Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

1 reference

12 December 2020

Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program

1 reference

12 December 2020

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

1 reference

12 December 2020

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

1 reference

12 December 2020

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

1 reference

12 December 2020

The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis

1 reference

12 December 2020

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females

1 reference

12 December 2020

Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case–control study

1 reference

12 December 2020

Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies

1 reference

12 December 2020

Safety of quadrivalent human papillomavirus vaccine administered routinely to females

1 reference

12 December 2020

Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination

1 reference

12 December 2020

Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil

1 reference

12 December 2020

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women

1 reference

12 December 2020

Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women

1 reference

12 December 2020

Autoimmune neuromyotonia following human papilloma virus vaccination

1 reference

12 December 2020

Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010.

1 reference

12 December 2020

Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease

1 reference

12 December 2020

Safety of human papillomavirus vaccines: a review.

1 reference

12 December 2020

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women

1 reference

12 December 2020

A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.

1 reference

12 December 2020

No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus

1 reference

12 December 2020

Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants

1 reference

12 December 2020

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

1 reference

12 December 2020

Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK.

1 reference

12 December 2020

Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States

1 reference

12 December 2020

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study

1 reference

12 December 2020

Safety of the quadrivalent human papillomavirus vaccine

1 reference

12 December 2020

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

1 reference

12 December 2020

Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems

1 reference

12 December 2020

Human papilloma virus vaccine associated uveitis

1 reference

12 December 2020

Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects

1 reference

12 December 2020

Motor palsies of cranial nerves (excluding VII) after vaccination: reports to the US Vaccine Adverse Event Reporting System.

1 reference

12 December 2020

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial

1 reference

12 December 2020

Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus

1 reference

12 December 2020

On the association between human papillomavirus vaccine and primary ovarian failure.

1 reference

12 December 2020

Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women

1 reference

12 December 2020

Adverse events following immunization in Ontario's female school-based HPV program

1 reference

12 December 2020

[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)]

1 reference

12 December 2020

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

1 reference

12 December 2020

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

1 reference

12 December 2020

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women

1 reference

12 December 2020

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.

1 reference

12 December 2020

Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Cervical Cancer Vaccine in Malaysian Women Aged 18-35 years: A Randomized Controlled Trial

1 reference

12 December 2020

Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism

1 reference

12 December 2020

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial

1 reference

12 December 2020

Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States

1 reference

12 December 2020

Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis

1 reference

12 December 2020

Long-term study of a quadrivalent human papillomavirus vaccine

1 reference

12 December 2020

Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.

1 reference

12 December 2020

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

1 reference

12 December 2020

Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine

1 reference

12 December 2020

Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases

1 reference

12 December 2020

Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands

1 reference

12 December 2020

The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems

1 reference

12 December 2020

A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder?

1 reference

12 December 2020

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.

1 reference

12 December 2020

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.

1 reference

12 December 2020

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination

1 reference

12 December 2020

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study

1 reference

12 December 2020

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial

1 reference

12 December 2020

Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.

1 reference

12 December 2020

A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events

1 reference

12 December 2020

Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.

1 reference

12 December 2020

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

1 reference

12 December 2020

The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine

1 reference

12 December 2020

Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA).

1 reference

12 December 2020

An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.

1 reference

12 December 2020

Research trends in evidence-based medicine: a joinpoint regression analysis of more than 50 years of publication data

1 reference

12 December 2020

Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine

1 reference

12 December 2020

Suspected side effects to the quadrivalent human papilloma vaccine

1 reference

12 December 2020

Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus

1 reference

12 December 2020

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

1 reference

12 December 2020

Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine

1 reference

12 December 2020

How to best measure the effectiveness of male human papillomavirus vaccine programmes?

1 reference

12 December 2020

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial

1 reference

12 December 2020

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.

1 reference

12 December 2020

Immunogenicity and Safety of a 9-Valent HPV Vaccine

1 reference

12 December 2020

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.

1 reference

12 December 2020

HPV vaccination crisis in Japan

1 reference

12 December 2020

Immunogenicity and safety of the 9-valent HPV vaccine in men.

1 reference

12 December 2020

Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom

1 reference

12 December 2020

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)

1 reference

12 December 2020

Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines

1 reference

12 December 2020

Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study

1 reference

12 December 2020

HPV vaccination syndrome. A questionnaire-based study

1 reference

12 December 2020

Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis

1 reference

12 December 2020

Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.

1 reference

12 December 2020

Proposed HPV vaccination syndrome is unsubstantiated

1 reference

12 December 2020

Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data.

1 reference

12 December 2020

Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.

1 reference

12 December 2020

Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females

1 reference

12 December 2020

Global Vaccine Safety Assessment: Challenges and Opportunities

1 reference

12 December 2020

The world must accept that the HPV vaccine is safe

1 reference

12 December 2020

Human papillomavirus vaccination and primary ovarian insufficiency: an association based on ideology rather than evidence

1 reference

12 December 2020

Interstitial lung disease associated with human papillomavirus vaccination

1 reference

12 December 2020

Adverse event monitoring of the human papillomavirus vaccines in Scotland

1 reference

12 December 2020

HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence

1 reference

12 December 2020

Anaphylaxis After Immunization of Children and Adolescents in Germany.

1 reference

12 December 2020

Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults.

1 reference

12 December 2020

Adverse events following HPV vaccination, Alberta 2006-2014.

1 reference

12 December 2020

Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.

1 reference

12 December 2020

Sudden-Onset Sensorineural Hearing Loss after Immunization: A Case-Centered Analysis.

1 reference

12 December 2020

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

1 reference

12 December 2020

Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013.

1 reference

12 December 2020

Tubulointerstitial Nephritis and Uveitis Syndrome Associated With Human Papillomavirus Vaccine.

1 reference

12 December 2020

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience

1 reference

12 December 2020

Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials

1 reference

12 December 2020

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.

1 reference

12 December 2020

Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.

1 reference

12 December 2020

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature.

1 reference

12 December 2020

Social mobilisation, consent and acceptability: a review of human papillomavirus vaccination procedures in low and middle-income countries.

1 reference

12 December 2020

Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®

1 reference

12 December 2020

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance

1 reference

12 December 2020

No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England

1 reference

12 December 2020

Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes

1 reference

12 December 2020

Human papillomavirus vaccines: WHO position paper, May 2017

1 reference

12 December 2020

Meeting of the Global Advisory Committee on Vaccine Safety, 7–8 June 2017

1 reference

12 December 2020

Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in Japan

1 reference

12 December 2020

Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France

1 reference

12 December 2020

Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA).

1 reference

12 December 2020

10.1007/S40264-017-0625-Z

Identifiers

DOI

1 reference

21 February 2018

Dimensions Publication ID

1100077899

0 references

1 reference

21 February 2018